VALIDATION OF A CLINICOPATHOLOGICALSCORE FOR THE PREDICTION OF POST-SURGICAL EVOLUTION OF PITUITARY ADENOMA: RETROSPECTIVE ANALYSIS ON 566 PATIENTS FROM A TERTIARY CARE CENTRE

Sofia Asioli, Alberto Righi, Marica Iommi, Chiara Baldovini, Francesca Ambrosi, Federica Guaraldi, Matteo Zoli, Diego Mazzatenta, Marco Faustini-Fustini, Paola Rucci, Caterina Giannini, Maria Pia Foschini

Research output: Contribution to journalArticle

Abstract

A clinicopathological score has been proposed by Trouillas et al. to predict the evolution of pituitary adenomas. Aim of our study was to perform an independent external validation of this score and identify other potential predictor of post-surgical outcome. The study sample included 566 patients with pituitary adenomas, specifically 253 FSH/LH-secreting, 147 GH-secreting, 85 PRL-secreting, 72 ACTH-secreting and 9 TSH-secreting tumours with at least 3-year post-surgical follow-up. In 437 cases, pituitary adenomas were non-invasive, with low (grade 1a, 378 cases) or high (grade 1b, 59 cases) proliferative activity. In 129 cases, tumours were invasive, with low (grade 2a, 87 cas-es) or high (grade 2b, 42 cases) proliferative activity. During the follow-up (mean 5.8 years), 60 pa-tients developed disease recurrence or progression, with a total of 130 patients with pituitary disease at last follow-up. Univariate analysis demonstrated a significantly higher risk of disease persistence and recurrence/progression in patients with PRL-, ACTH- and FSH/LH-secreting tumours as com-pared to those with somatotroph tumours, and in those with high proliferative activity (grade 1b and 2b) or >1 cm diameter. Multivariate analysis confirmed tumour type and grade to be independent predictors of disease free-survival. Tumour invasion, Ki-67 and tumour type were the only independent prognostic factors of disease-free survival. Our data confirmed the validity of Trouillas' score, being tumour type and grade independent pre-dictors of disease evolution. Therefore, we recommend to always consider both features, together with tumour histological subtype, in the clinical setting to early identify patients at higher risk of recurrence.

Original languageEnglish
Pages (from-to)127-134
Number of pages8
JournalEuropean Journal of Endocrinology
Volume180
Issue number2
DOIs
Publication statusE-pub ahead of print - Nov 1 2018

Fingerprint

Pituitary Neoplasms
Tertiary Care Centers
Neoplasms
Recurrence
Adrenocorticotropic Hormone
Disease-Free Survival
Pituitary Diseases
Somatotrophs
Multivariate Analysis

Cite this

VALIDATION OF A CLINICOPATHOLOGICALSCORE FOR THE PREDICTION OF POST-SURGICAL EVOLUTION OF PITUITARY ADENOMA: RETROSPECTIVE ANALYSIS ON 566 PATIENTS FROM A TERTIARY CARE CENTRE. / Asioli, Sofia; Righi, Alberto; Iommi, Marica; Baldovini, Chiara; Ambrosi, Francesca; Guaraldi, Federica; Zoli, Matteo; Mazzatenta, Diego; Faustini-Fustini, Marco; Rucci, Paola; Giannini, Caterina; Foschini, Maria Pia.

In: European Journal of Endocrinology, Vol. 180, No. 2, 01.11.2018, p. 127-134.

Research output: Contribution to journalArticle

Asioli, Sofia ; Righi, Alberto ; Iommi, Marica ; Baldovini, Chiara ; Ambrosi, Francesca ; Guaraldi, Federica ; Zoli, Matteo ; Mazzatenta, Diego ; Faustini-Fustini, Marco ; Rucci, Paola ; Giannini, Caterina ; Foschini, Maria Pia. / VALIDATION OF A CLINICOPATHOLOGICALSCORE FOR THE PREDICTION OF POST-SURGICAL EVOLUTION OF PITUITARY ADENOMA: RETROSPECTIVE ANALYSIS ON 566 PATIENTS FROM A TERTIARY CARE CENTRE. In: European Journal of Endocrinology. 2018 ; Vol. 180, No. 2. pp. 127-134.
@article{1f9e2328db0d48cbbc948ae0454d9891,
title = "VALIDATION OF A CLINICOPATHOLOGICALSCORE FOR THE PREDICTION OF POST-SURGICAL EVOLUTION OF PITUITARY ADENOMA: RETROSPECTIVE ANALYSIS ON 566 PATIENTS FROM A TERTIARY CARE CENTRE",
abstract = "A clinicopathological score has been proposed by Trouillas et al. to predict the evolution of pituitary adenomas. Aim of our study was to perform an independent external validation of this score and identify other potential predictor of post-surgical outcome. The study sample included 566 patients with pituitary adenomas, specifically 253 FSH/LH-secreting, 147 GH-secreting, 85 PRL-secreting, 72 ACTH-secreting and 9 TSH-secreting tumours with at least 3-year post-surgical follow-up. In 437 cases, pituitary adenomas were non-invasive, with low (grade 1a, 378 cases) or high (grade 1b, 59 cases) proliferative activity. In 129 cases, tumours were invasive, with low (grade 2a, 87 cas-es) or high (grade 2b, 42 cases) proliferative activity. During the follow-up (mean 5.8 years), 60 pa-tients developed disease recurrence or progression, with a total of 130 patients with pituitary disease at last follow-up. Univariate analysis demonstrated a significantly higher risk of disease persistence and recurrence/progression in patients with PRL-, ACTH- and FSH/LH-secreting tumours as com-pared to those with somatotroph tumours, and in those with high proliferative activity (grade 1b and 2b) or >1 cm diameter. Multivariate analysis confirmed tumour type and grade to be independent predictors of disease free-survival. Tumour invasion, Ki-67 and tumour type were the only independent prognostic factors of disease-free survival. Our data confirmed the validity of Trouillas' score, being tumour type and grade independent pre-dictors of disease evolution. Therefore, we recommend to always consider both features, together with tumour histological subtype, in the clinical setting to early identify patients at higher risk of recurrence.",
author = "Sofia Asioli and Alberto Righi and Marica Iommi and Chiara Baldovini and Francesca Ambrosi and Federica Guaraldi and Matteo Zoli and Diego Mazzatenta and Marco Faustini-Fustini and Paola Rucci and Caterina Giannini and Foschini, {Maria Pia}",
year = "2018",
month = "11",
day = "1",
doi = "10.1530/EJE-18-0749",
language = "English",
volume = "180",
pages = "127--134",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "2",

}

TY - JOUR

T1 - VALIDATION OF A CLINICOPATHOLOGICALSCORE FOR THE PREDICTION OF POST-SURGICAL EVOLUTION OF PITUITARY ADENOMA: RETROSPECTIVE ANALYSIS ON 566 PATIENTS FROM A TERTIARY CARE CENTRE

AU - Asioli, Sofia

AU - Righi, Alberto

AU - Iommi, Marica

AU - Baldovini, Chiara

AU - Ambrosi, Francesca

AU - Guaraldi, Federica

AU - Zoli, Matteo

AU - Mazzatenta, Diego

AU - Faustini-Fustini, Marco

AU - Rucci, Paola

AU - Giannini, Caterina

AU - Foschini, Maria Pia

PY - 2018/11/1

Y1 - 2018/11/1

N2 - A clinicopathological score has been proposed by Trouillas et al. to predict the evolution of pituitary adenomas. Aim of our study was to perform an independent external validation of this score and identify other potential predictor of post-surgical outcome. The study sample included 566 patients with pituitary adenomas, specifically 253 FSH/LH-secreting, 147 GH-secreting, 85 PRL-secreting, 72 ACTH-secreting and 9 TSH-secreting tumours with at least 3-year post-surgical follow-up. In 437 cases, pituitary adenomas were non-invasive, with low (grade 1a, 378 cases) or high (grade 1b, 59 cases) proliferative activity. In 129 cases, tumours were invasive, with low (grade 2a, 87 cas-es) or high (grade 2b, 42 cases) proliferative activity. During the follow-up (mean 5.8 years), 60 pa-tients developed disease recurrence or progression, with a total of 130 patients with pituitary disease at last follow-up. Univariate analysis demonstrated a significantly higher risk of disease persistence and recurrence/progression in patients with PRL-, ACTH- and FSH/LH-secreting tumours as com-pared to those with somatotroph tumours, and in those with high proliferative activity (grade 1b and 2b) or >1 cm diameter. Multivariate analysis confirmed tumour type and grade to be independent predictors of disease free-survival. Tumour invasion, Ki-67 and tumour type were the only independent prognostic factors of disease-free survival. Our data confirmed the validity of Trouillas' score, being tumour type and grade independent pre-dictors of disease evolution. Therefore, we recommend to always consider both features, together with tumour histological subtype, in the clinical setting to early identify patients at higher risk of recurrence.

AB - A clinicopathological score has been proposed by Trouillas et al. to predict the evolution of pituitary adenomas. Aim of our study was to perform an independent external validation of this score and identify other potential predictor of post-surgical outcome. The study sample included 566 patients with pituitary adenomas, specifically 253 FSH/LH-secreting, 147 GH-secreting, 85 PRL-secreting, 72 ACTH-secreting and 9 TSH-secreting tumours with at least 3-year post-surgical follow-up. In 437 cases, pituitary adenomas were non-invasive, with low (grade 1a, 378 cases) or high (grade 1b, 59 cases) proliferative activity. In 129 cases, tumours were invasive, with low (grade 2a, 87 cas-es) or high (grade 2b, 42 cases) proliferative activity. During the follow-up (mean 5.8 years), 60 pa-tients developed disease recurrence or progression, with a total of 130 patients with pituitary disease at last follow-up. Univariate analysis demonstrated a significantly higher risk of disease persistence and recurrence/progression in patients with PRL-, ACTH- and FSH/LH-secreting tumours as com-pared to those with somatotroph tumours, and in those with high proliferative activity (grade 1b and 2b) or >1 cm diameter. Multivariate analysis confirmed tumour type and grade to be independent predictors of disease free-survival. Tumour invasion, Ki-67 and tumour type were the only independent prognostic factors of disease-free survival. Our data confirmed the validity of Trouillas' score, being tumour type and grade independent pre-dictors of disease evolution. Therefore, we recommend to always consider both features, together with tumour histological subtype, in the clinical setting to early identify patients at higher risk of recurrence.

U2 - 10.1530/EJE-18-0749

DO - 10.1530/EJE-18-0749

M3 - Article

C2 - 30481158

VL - 180

SP - 127

EP - 134

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -